scout
|Articles|February 1, 2008

Oncology NEWS International

  • Oncology NEWS International Vol 17 No 2
  • Volume 17
  • Issue 2

Kosan opens TIME-1 pivotal trial of tanespimycin in myeloma

Kosan Biosciences Incorporated has announced that the Tanespimycin in Myeloma Evaluation (TIME-1) pivotal phase III trial for its Hsp90 inhibitor tanespimycin as a potential treatment for multiple myeloma is open for enrollment

HAYWARD, California—Kosan Biosciences Incorporated has announced that the Tanespimycin in Myeloma Evaluation (TIME-1) pivotal phase III trial for its Hsp90 inhibitor tanespimycin as a potential treatment for multiple myeloma is open for enrollment. Approximately 470 patients with first-relapse disease will be randomized to treatment with bortezomib (Velcade) plus tanespimycin or bortezomib alone.

Articles in this issue

almost 18 years ago

NLST article not balanced, critic of screening trial asserts

almost 18 years ago

M.D. Anderson and AstraZeneca form neuropathic pain alliance

almost 18 years ago

Good nilotinib responses in imatinib-resistant AP-CML

almost 18 years ago

Virus linked to Merkel cell carcinoma

almost 18 years ago

Benefit of adjuvant RT/CT for pancreatic ca affirmed

almost 18 years ago

Recurrence Score helps select node+ pts for chemo

almost 18 years ago

For resectable liver mets: Preop chemotherapy or not?

almost 18 years ago

Plerixafor boosts stem cell mobilization in myeloma pts

almost 18 years ago

MRI shows second-hand smoke damage

almost 18 years ago

Assay has high sensitivity for hard-to-detect SLN mets

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Related Content